Celgene Europe BV - search results

European Union - English - EMA (European Medicines Agency)

azacitidine celgene

celgene europe bv - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastic agents - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

European Union - English - EMA (European Medicines Agency)

refludan

celgene europe ltd. - lepirudin - thromboembolism; thrombocytopenia - antithrombotic agents - anticoagulation in adult patients with heparin-induced thrombocytopenia type ii and thromboembolic disease mandating parenteral antithrombotic therapy.the diagnosis should be confirmed by the heparin-induced platelet activation assay or an equivalent test.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

thalidomide celgene 50mg capsules

celgene ltd - thalidomide - capsule - 50mg

Israel - English - Ministry of Health

thalidomide celgene 50 mg hard capsules

neopharm ltd - thalidomide - hard capsule - thalidomide 50 mg - thalidomide - multiple myeloma : 1. for the treatment of multiple myeloma after failure of standars therapies. 2. thalidomide celgene 50 mg hard capsules in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma. 3. thalidomide celgene in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma > or = 65 years or ineligible for high dose chemotherapy. erythema nodosum leprosum: 4. for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl). thalidomide is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis. it is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence.בקשה לעדכון משטר מינון 4/2/2020

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

vidaza 100mg powder for suspension for injection vials

celgene ltd - azacitidine - powder for suspension for injection - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abraxane 100mg powder for suspension for infusion vials

celgene ltd - paclitaxel albumin - powder for suspension for infusion - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

imnovid 1mg capsules

celgene ltd - pomalidomide - capsule - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

imnovid 2mg capsules

celgene ltd - pomalidomide - capsule - 2mg